RCL
87
4
URI
72
3
DLTR
31
-3
CHD
48
3
UNH
67
3
RRC
58
5
ESS
65
5
XRX
37
2
COST
66
6
IBM
53
2
ICE
59
2
JBHT
68
3
NTRS
57
-2
VRSK
84
9
GOOG
71
-6
CVS
44
-4
ORCL
71
2
SBUX
39
7
KMI
81
2
T
45
4
RCL
87
4
URI
72
3
DLTR
31
-3
CHD
48
3
UNH
67
3
RRC
58
5
ESS
65
5
XRX
37
2
COST
66
6
IBM
53
2
ICE
59
2
JBHT
68
3
NTRS
57
-2
VRSK
84
9
GOOG
71
-6
CVS
44
-4
ORCL
71
2
SBUX
39
7
KMI
81
2
T
45
4
Financhill
Back

Phathom Pharmaceuticals 10K Form

Sell
44

PHAT
Phathom Pharmaceuticals

Last Price:
16.85
Seasonality Move:
-6.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PHAT News And Ratings

See the #1 stock for the next 7 days that we like better than PHAT

PHAT Financial Statistics

Sales & Book Value

Annual Sales: $682K
Cash Flow: $-63.62M
Price / Cash Flow: 0
Annual Sales: $-2.74
Price / Book: 0

Profitability

EPS (TTM): -5.75000
Net Income (TTM): $-339.45M
Gross Margin: $515K
Return on Equity: 0%
Return on Assets: -91.94%

Phathom Pharmaceuticals Earnings Forecast

Key Phathom Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PHAT is 75.51%.
  • The Selling, General & Administrative Expenses for PHAT have been equal to 17,291.50% of Gross Profit Margin.
  • The Research & Development expenses have been 7,316.57% of Revenue.
  • The Interest Expense is -20.82% of Operating Income.
  • The Net Earning history of PHAT is -29,558.94% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Phathom Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PHAT
CUSIP: 71722W
Website: phathompharma.com

Debt

Debt-to-Equity Ratio: -0.94
Current Ratio: 5.73
Quick Ratio: 5.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PHAT Technical Analysis vs Fundamental Analysis

Sell
44
Phathom Pharmaceuticals (PHAT) is a Sell

Is Phathom Pharmaceuticals a Buy or a Sell?